Floatz logo

Epirubicin

MPN

OHSU Knight Cancer InstitutePhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the MPN cohort.

Asset / SponsorPhaseRating
Pembrolizumab
OHSU Knight Cancer Institute
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Incyte Corporation
Phase 1/2CCC
Retifanlimab
Incyte Corporation
Phase 1/2CCC
Pemigatinib
Incyte Corporation
Phase 1/2CCC
Rgi-2001
Zachariah Michael DeFilipp
Phase 1CC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →